Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Enteric Coated Aspirin Clear all

Conditions: Platelet Aggregation
Interventions: Aspirin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Preeclampsia, Pregnancy Related
Interventions: Aspirin 81Mg Ec Tab, Aspirin 162Mg Ec Tab; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Platelet Inhibition
Interventions: PN400, ASA, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Acute Coronary Syndrome
Interventions: Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 49
States / cities: Alexander City, Alabama • Banning, California • Sylmar, California + 46 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin; Dietary Supplement · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Volunteers
Interventions: ASA, non-enteric-coated chewable aspirin; Drug
Lead sponsor: Vectura, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Springfield, Missouri

Conditions: Myeloma
Interventions: Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up; Drug · Other
Lead sponsor: Robert Redner, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 22
States / cities: Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more

Conditions: Cancer
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 65 Years and older
Enrollment: 14,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 40
States / cities: Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Artery Disease
Interventions: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires; Drug · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 2,476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 80
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more

Conditions: Breast Cancer Survivors
Interventions: Aspirin, Omega 3 FFA; Drug · Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Preeclampsia
Interventions: Aspirin 81Mg Non-enteric coated Tab; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 13 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Thromboembolism
Interventions: Aspirin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 19 Years and older
Enrollment: 5,478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Coronary Artery Disease, Myocardial Infarction
Interventions: Ticagrelor, ASA; Drug
Lead sponsor: Juan Badimon; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: enteric-coated aspirin, Chewable aspirin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiovascular Risk Factor, C.Medical Procedure; Vascular, Functional or Late, Electrolyte and Fluid Balance Conditions
Interventions: 81 mg enteric coated aspirin; Drug
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 40 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Healthy Volunteers
Interventions: PL-ASA; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pulmonary Embolism, Venous Thrombosis
Interventions: Enteric Coated Aspirin, Warfarin, Rivaroxaban; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 18,883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b, Rintatolimod; Drug · Procedure · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Foramen Ovale, Patent
Interventions: Aspirin, Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastric Ulcer
Interventions: PA32540, EC Aspirin 325; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Measurement of Platelet Dense Granule Release in Healthy Volunteers

Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

ASPREE Cancer Endpoints Study

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Impact of COX2 on Sera Biomarkers From Obese Subjects

Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Platelet Sub-study of the TWILIGHT Trial

Aspirin Resistance in Coronary Artery Disease

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers